Guided Therapeutics (GTHP) EBIT Margin (2010 - 2025)
Guided Therapeutics recorded quarterly EBIT Margin of 120.34% in Q4 2025, up 85.11% quarter-over-quarter from 808.33% in Q3 2025, and up 5327966.0% year-over-year from N/an in Q4 2024.
Guided Therapeutics' EBIT Margin history runs 16 years deep, the most recent figure standing at 120.34% for Q4 2025.
- In Q4 2025, EBIT Margin rose 5327966.0% year-over-year to 120.34%; the TTM figure through Dec 2025 stood at 309.26% (up 2981931.0% YoY), while the FY2025 annual figure was 309.26%, up 2980503.0% from the prior year.
- EBIT Margin came in at 120.34% for Q4 2025 at Guided Therapeutics, up from 808.33% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 120.34% in Q4 2025 to a low of 53400.0% in Q4 2024.
- A 5-year average of 11790.73% and a median of 3626.14% in 2023 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin sank 5188438 bps in 2024 and soared 5327966 bps in 2025, its largest moves.
- Guided Therapeutics' EBIT Margin stood at 725.0% in 2021, then plunged by 5528 bps to 40800.0% in 2022, then jumped by 96 bps to 1515.62% in 2023, then sank by 3423 bps to 53400.0% in 2024, then surged by 100 bps to 120.34% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 120.34%, 808.33%, and 652.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -120.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.34% |
| Sep 30, 2025 | -808.33% |
| Jun 30, 2025 | -652.14% |
| Dec 31, 2024 | -53,400.00% |
| Mar 31, 2024 | -5,983.33% |
| Dec 31, 2023 | -1,515.63% |
| Jun 30, 2023 | -3,420.45% |
| Mar 31, 2023 | -3,831.82% |
| Sep 30, 2022 | -40,800.00% |
| Jun 30, 2022 | -14,340.00% |
| Mar 31, 2022 | -8,860.00% |
| Dec 31, 2021 | -725.00% |
| Sep 30, 2021 | -2,563.16% |
| Jun 30, 2021 | -28,050.00% |
| Dec 31, 2020 | -1,152.00% |
| Sep 30, 2020 | -198.70% |
| Dec 31, 2019 | -1,031.25% |
| Sep 30, 2019 | -18,800.00% |
| Jun 30, 2019 | -32,700.00% |
| Mar 31, 2019 | -1,427.78% |
| Dec 31, 2018 | -1,069.05% |
| Sep 30, 2018 | -11,700.00% |
| Jun 30, 2018 | -6,137.50% |
| Mar 31, 2018 | -9,400.00% |
| Dec 31, 2017 | -683.18% |
| Sep 30, 2017 | -4,057.58% |
| Jun 30, 2017 | -612.64% |
| Mar 31, 2017 | -2,447.62% |
| Dec 31, 2016 | 229.22% |
| Sep 30, 2016 | -714.74% |
| Dec 31, 2015 | -17,155.56% |
| Sep 30, 2015 | -22,975.00% |
| Jun 30, 2015 | -16,010.00% |
| Mar 31, 2015 | -9,920.00% |
| Dec 31, 2014 | -16,530.77% |
| Sep 30, 2014 | -10,977.27% |
| Jun 30, 2014 | -18,427.27% |
| Mar 31, 2014 | -10,942.11% |
| Dec 31, 2013 | -390.17% |
| Sep 30, 2013 | -1,906.98% |
| Jun 30, 2013 | -784.23% |
| Mar 31, 2013 | -1,122.75% |
| Dec 31, 2012 | -115.32% |
| Sep 30, 2012 | -139.97% |
| Jun 30, 2012 | -125.46% |
| Mar 31, 2012 | -138.72% |
| Dec 31, 2011 | -321.65% |
| Sep 30, 2011 | -259.45% |
| Jun 30, 2011 | -53.12% |
| Mar 31, 2011 | -96.48% |
| Jun 30, 2010 | -65.96% |